XLO — Xilio Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $38.84m
- -$16.45m
- $6.34m
Annual cashflow statement for Xilio Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -55.2 | -75.8 | -88.2 | -76.4 | -58.2 |
| Depreciation | |||||
| Non-Cash Items | 1.46 | 5.35 | 8.65 | 7.54 | 6.44 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 16.6 | -11.8 | 2 | -1.66 | 31.8 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -36.1 | -80.8 | -75.7 | -68.6 | -18.4 |
| Capital Expenditures | -2.19 | -1.1 | -1.87 | -0.486 | -0.036 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -2.19 | -1.1 | -1.87 | -0.486 | -0.036 |
| Financing Cash Flow Items | — | -0.75 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10 | 261 | -0.069 | -6.55 | 29.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -28.3 | 179 | -77.7 | -75.7 | 10.8 |